Skip to content

Study · In vitro (cells) · rat · 2001

1 result

Mechanisms of age-related decline in insulin-like growth factor-I dependent proteoglycan synthesis in rat intervertebral disc cells.

Okuda S, Myoui A, Ariga K, Nakase T, Yonenobu K, Yoshikawa H

Spine1 Nov 2001Cited by 66 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In cultured rat nucleus pulposus cells from 40-week-old animals, Long R3 IGF-I upregulated proteoglycan synthesis compared with IGF-I.

    In plain wordsIn rat disc cells grown in a dish, an IGF-I analogue raised proteoglycan synthesis more than natural IGF-I did.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseProteoglycan synthesis in 40-week cells
    Study

    ratn: not reported in source

    cultured nucleus pulposus cells from 40-week-old rats
    Comparator
    IGF-I
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, proteoglycan synthesis in 40-week cells supplemented with Long R3 insulin-like growth factor-I was upregulated in comparison with that in 40-week cells supplemented with insulin-like growth factor-I.
    2 context sentences
    Summary · context
    Nucleus pulposus tissue and cells were obtained from the coccygeal vertebrae of 8-week-old, 40-week-old, and 120-week-old rats.
    Summary · context
    Thus, the expression of insulin-like growth factor binding protein-1 and proteoglycan synthesis was investigated by use of Long R3 insulin-like growth factor-I, which was not influenced by insulin-like growth factor binding proteins.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.